Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

t on Form 10-K for the year ended December 31, 2011 and Form 10-Q for the quarter ended September 30, 2012. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

 NEUROCRINE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three Months EndedDecember 31, Year EndedDecember 31, 2012201120122011Revenues:Sponsored research and development

$
3,959

$
,873

$
8,897

$
,462Milestones and license fees

7,988

9,237

34,243

66,951Total revenues

21,947

11,110

53,140

77,413Operating expenses:Research and development

9,097

8,002

37,163

30,951General and administrative

3,311

2,668

13,437

12,458Cease-use expense

957

(7)

1,092

82Total operating expenses

13,365

10,663

51,692

43,491Income from operations

8,582

447

1,448

33,922Other income:Gain on sale/disposal of assets

7

58

32

242Deferred gain on real estate

766

744

3,042

2,953Investment income, net

130

77

489

418Other income, net

5

5

14

36Total other income

908

884

3,577

3,649Net income

$
9,490

$
,331

$
5,025

$
37,571Net income per common share:Basic

$
.14

$
.02

$
.08

$
.68Diluted

$
.14

$
.02

$
.08

$
.67Shares used in the calculation of net income per common share:Basic

66,406

55,259

65,619

55,176Diluted

67,720

56,461

66
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Asterias Biotherapeutics, Inc. (NYSE MKT: ... a Notice of Grant Award (NGA) with the ... 1, 2014.  The NGA provides for the immediate ... of additional grant funds pursuant to the previously ... development of Asterias, product, AST-OPC1. The grant provides ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Latin ... the market in Latin America with analysis and forecast ... in 2013, and is expected to reach $2,366.8 million ... to 2018. , Browse through the TOC of the ... idea of the in-depth analysis provided. It also provides ...
(Date:10/19/2014)... Asian Automatic patient billing report defines and segments the ... The Automatic patient billing market in Asia is estimated ... a developing CAGR of 7.2% from 2013 to 2018. ... patient billing market, to get an idea of the ... the segmentation of this market in the same region, ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3
... 11 Genta,Incorporated (Nasdaq: GNTA ) announced ... institutional investors to sell 6 million shares,of common ... totaling,approximately $3.1 million before fees and expenses. The ... February 13, 2008, subject to the,satisfaction of customary ...
... over Same Quarter Last Year - ... - FY08 Revenue Guidance Raised - - ... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), a medical device company ... dysfunction,today reported record net sales of $3.7 million for the third quarter ...
... This week, Summit VetPharm,identified the first instance ... Vectra 3D(TM) flea and tick product. This situation,where ... popular website targeting,pet owners, is a clear violation ... after confirming the identity of the California,veterinarian, swiftly ...
Cached Biology Technology:Genta Announces Common Stock Offering of Approximately $3.1 Million 2Genta Announces Common Stock Offering of Approximately $3.1 Million 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 2Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 3Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 4Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 5Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 6Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 7Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 8Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 9Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007 10Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 2Summit VetPharm Addressed Veterinarian Diverted Vectra 3D(TM) 3
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... the structure of unknown natural compounds is a slow ... but this may now change thanks to a new ... University of California, San Diego and presented at RECOMB ... in Singapore. UC San Diego researchers have devised ...
... have just confirmed what poets have known for centuries: eyes ... brain. In a new study published in the April 2008 ... Harvard researchers describe the development of gene probe eye ... detect tissue repair in the brain of living organisms using ...
... known that the left and right sides of the brain ... influence cognitive performance and social behaviour. For instance, in humans, ... processing whereas the right side is better at comprehending musical ... work in the open access journal Neural Development have pinpointed ...
Cached Biology News:UC San Diego researchers eliminate drug discovery bottleneck 2UC San Diego researchers eliminate drug discovery bottleneck 3UC San Diego researchers eliminate drug discovery bottleneck 4Harvard researchers publish MRI images of genes in action in the living brain 2Neurons hard wired to tell left from right 2
iNOS/NOS Type II Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 150 µg Consult technical datasheet for details....
Cell Culture Flask, 75 cm, treated polystyrene...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... virtually every research laboratory, the revolutionary Luminex ... accurately, inexpensively and in real time enhancing ... analysis system includes the Luminex 100, the ... xMAP technology which enables you to simultaneously ...
Biology Products: